Real‑life cost and cost‑effectiveness for tiotropium 18 μg od monotherapy in moderate and severe COPD patients: a 48‑month survey. (2014). Farmeconomia. Health Economics and Therapeutic Pathways, 15(2), 39-44. https://doi.org/10.7175/fe.v15i2.924